Navigation Links
Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity
Date:12/1/2008

St. Jude study shows the Prox1 gene is a two-way switch that, if turned off, causes lymphatic endothelial cells to be reprogrammed so that they lose their identity and become more like blood endothelial cells

MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswire/ --Scientists at St. Jude Children's Research Hospital have discovered that a certain differentiated cell type is so ready to change its identity that it requires the constant expression of a gene called Prox1 to dissuade it.

The researchers showed that Prox1 acts as a two-way switch whose inactivity is sufficient to reprogram a specialized type of cell, called a lymphatic endothelial cell (LEC). In the absence of active Prox1, the LEC actually loses its identity and assumes characteristics of a blood endothelial cell (BEC), which plays a different role in the body. Endothelial cells line the inside of blood and lymphatic vessels. The results of the study appear in the Dec. 1, 2008, issue of the journal Genes & Development.

The new finding is important because it helps to explain how during embryogenesis a critical set of vessels called the lymphatic vasculature arises from veins; and how lymphatic vessels can eventually lose their characteristics and acquire features typical of blood vessels and transport blood -- a trick that might, for example, let the body quickly build up a supply of additional blood vessels when there is an emergency need for more nourishment in a certain area. A switch from lymphatic to blood vessels might also be triggered by certain tumors trying to nourish their own growth.

The lymphatic vasculature is a vital network of vessels that performs important housekeeping functions in the body. Specifically, it drains fluids that normally escape from capillaries, which provide nutrients to the body's cells. The lymphatic vasculature is also part of the immune system that
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
5. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
6. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
9. RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION
10. Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments
11. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...6 The Michael J. Fox Fo...four industry research teams for pre-clinical rese...isease. , , The funding was awarded under the F... This program, first launched in 2006, supports an... research. TDI is part of MJFF,s focus on ,de-...
(Date:1/5/2009)... 5 Cylene Pharmaceuticals announce...rial of its oral CK2 protein kinase inhibitor, CX-...leman,s disease, or multiple myeloma. The primary ...termination of safety, tolerance and PK properties... Phase II trials. In addition, multiple mechanism-...
(Date:12/29/2008)...Dec. 29 The winner of t...tection was announced today by Dr. Peter G. Goldsc...ment Institute. , , The winner of the annual a... Cancer Center -- for its best practice " IND Re...ovides for 1) enhanced human subjects protection, ...
(Date:12/17/2008)... show for the first time that normal stem cells ca...ues , , MEMPHIS, Tenn., Dec. 17 /PRNewswire...s Research Hospital have answered a central questi...n give rise to tumors. Stem cells are immature cel...re differentiated cells that compose the range of ...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 32008 Human Research Protection Award Recipients Announced 2Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source 2Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source 33 D photonic crystals will revolutionize telecommunications 1888 13 D photonic crystals will revolutionize telecommunications 1888 23 D photonic crystals will revolutionize telecommunications 1888 3Acting Surgeon General Encourages Americans to Know Their Health History During Fourth Annual Family History Day 6757 1Acting Surgeon General Encourages Americans to Know Their Health History During Fourth Annual Family History Day 6757 2Acting Surgeon General Encourages Americans to Know Their Health History During Fourth Annual Family History Day 6757 3MEDRAD Mobile MR Injector Meets Challenges of MR Trailers 6755 1MEDRAD Mobile MR Injector Meets Challenges of MR Trailers 6755 2Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 1Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 2Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 3Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 4Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 5Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 6Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 7Franklin 26 Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise 6753 8
(Date:1/8/2009)...ber Tom Torlakson Introduces AB 89 , , SACRAMEN...day, Lung Cancer Alliance-California (LCA-CA), hai...th District) for his continued leadership in intro...er research. For the third consecutive year, legi...ing considered in the California Legislature. ,...
(Date:1/8/2009)...dy could shape new treatments for secondary pneumo...wswire/ -- Scientists at St. Jude Children,s Resea...eatment for bacterial pneumonia following influenz... azithromycin, which kill bacteria by inhibiting t...standard first-line treatment with the "beta-lacta...
(Date:1/8/2009)...n hurtful comments, study suggests , , ...verestimate how strongly they would react to racis...ee percent of study participants at York Universit...iment with a white person rather than a black one,...about the black person when he left the room. ,...
(Date:1/8/2009)...ildren,s Research Hospital have demonstrated a mor...owing influenza. They found that the antibiotics c...y inhibiting their protein synthesis, are more eff...he "beta-lactam" antibiotic ampicillin, which caus...ng is important because pneumonia, rather than the...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Many Turn Blind Eye to Racism 2Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3
... had reported that the blood samples of autistic c...nents of the immunity system. This may be the firs... the blood tests of children. Autism spectrum diso... seen in a mild to the most sever form. The charac...
...hers say cholesterol may be actually needed to hel...ever researchers also say that too much of it coul...eries, where it builds up as plaque and can cause ...uggest an enzyme called ACAT2 may be to blame for ...
...regnancy not only decides the health// of the fetu...n as well. In a study to understand fetal developm...und out about long-term influence on the genetic c...ealth of the next few generations. Their research ...
... UK, has provided new guidelines //for dealing wit...uidelines suggest that psychological therapy be gi...ral or man made is always tough. NICE had emphasiz...thing shelter to these traumatized people it is al...
Other Medicine News:
Vannas Capsulotomy scissors angled
Gills-Vannas straight capsulotomy flat handle scissors
Vannas angled capsulotomy round handle scissors
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium.
Medicine Products: